BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Immunai and Parker Institute to Build Largest Single-Cell Dataset for Real-World Immunotherapy Research

by BiopharmaTrend   •   April 24, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# AI & Digital   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Immunai and the Parker Institute for Cancer Immunotherapy (PICI) have announced a collaboration to build what they describe as the world’s largest patient-centric single-cell dataset focused on standard-of-care immunotherapy.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

The project will analyze over 3,700 longitudinal blood samples from 1,070 patients treated with immune checkpoint inhibitors, drawn from PICI’s "RADIOHEAD" study—a multi-center, pan-cancer cohort conducted across 49 U.S. community oncology clinics.

The RADIOHEAD dataset includes patients with non-small cell lung cancer (~1,400 samples), melanoma (~500 samples), and other cancers. Samples are collected at three clinical timepoints: pretreatment, early on-treatment, and during immune-related adverse events. These are paired with detailed clinical and demographic data and subjected to multi-omic profiling—covering circulating tumor DNA, whole-exome sequencing, serum proteomics, transcriptomics, and high-dimensional immune profiling.

Immunai team

Immunai will perform single-cell RNA sequencing and integrate the data into its AMICA (Annotated Multi-omic Immune Cell Atlas) platform, which supports comparative immune analysis across diseases. The company will use 10x Genomics’ Chromium GEM-X technology for single-cell resolution and apply its proprietary AI tools to identify molecular patterns of immune response and resistance. The aim is to support the discovery of predictive biomarkers, uncover immune mechanisms of therapy failure, and guide more targeted immunotherapy strategies.

The resulting dataset will inform Immunai’s ImmunoDynamics Engine platform for immune modeling and help de-risk clinical development through better patient stratification and early-response prediction.

This announcement follows Immunai’s March 2025 appointment of Mikael Dolsten, former Chief Scientific Officer and President of R&D at Pfizer, to its Board of Directors. Immunai has previously partnered with AstraZeneca, Teva, and other major pharma players to support drug development decisions in oncology and autoimmune indications.

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.